Analyst firms · Leerink Partners · ABCL
Leerink Partners ABCL price target and rating history
AbCellera Biologics Inc. (ABCL) · Health Care
Leerink Partners rates AbCellera Biologics Inc. (ABCL) Market Perform with a $4 price target, as of its latest action on Nov 7, 2025. It has published 3 rating actions on ABCL since February 2022, including 0 upgrades and 1 downgrade. Across 5 firms with a ABCL price target in the last 12 months, the median target is $13.
- Current rating
- Market Perform
- Price target
- $4
- Median target, all firms
- $13
- Actions on ABCL
- 3
Leerink Partners price target on ABCL
Every Leerink Partners rating on ABCL
- Nov 7, 2025
- Jul 7, 2025
- Feb 25, 2022
How other firms rate ABCL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $19 | Nov 18, 2026 |
| UBS | Buy | $18 | Oct 12, 2026 |
| Goldman Sachs | Neutral | $13 | Sep 24, 2026 |
| The Benchmark Company | Buy | $11 | Jul 7, 2026 |
| Cantor Fitzgerald | Overweight | $7 | May 5, 2026 |
Questions about Leerink Partners and ABCL
- What is Leerink Partners's price target for ABCL?
- Leerink Partners's latest stated price target for AbCellera Biologics Inc. (ABCL) is $4, from its action on Nov 7, 2025.
- What is Leerink Partners's rating on ABCL?
- Leerink Partners rates ABCL Market Perform, a neutral rating, as of Nov 7, 2025.
- When did Leerink Partners last change its view on ABCL?
- On Nov 7, 2025, Leerink Partners downgrades to Market Perform from Outperform, price target $4.
- How does Leerink Partners's ABCL target compare with other analysts?
- Across 5 firms with a ABCL price target in the last 12 months, the median target is $13.
More ABCL rating histories
All Leerink Partners ratingsABCL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.